Realising the Broader Value of Vaccines in the UK

Brassel, S., Neri, M., O’Neill, P. and Steuten, L. 

Consulting Report
August 2020

Sign Up for the OHE News Bulletin

Why not sign up for our news bulletin? Around once a week we will send you a round-up of the latest news, events and publications from OHE.

I'm already signed up    No thanks

Many health technology assessment (HTA) agencies limit their assessment of vaccines to individual health benefits and the costs associated with vaccine administration and the disease avoided. However, compared to other health technologies, the standard evaluation approaches have often been criticised as inadequate to accurately estimate the value of vaccines.

This study uses a newly designed framework to capture the broader value of 10 selected vaccines with a high likelihood of entering the UK within the next decade. The findings qualify the critical gaps between value generation through vaccination and value recognition by relevant regulators. Recommendations are given to prevent the systematic undervaluation of future vaccines.